SB 202190 – 50 mg

Brand:
Cayman
CAS:
152121-30-7
Storage:
-20
UN-No:
Non-Hazardous - /

SB 202190 is a selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively.{21464,12847} When tested at 10 μM, SB 202190 has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs).{12847} Pyridinyl imidazole inhibitors, including this compound, directly bind p38 MAP kinases in the ATP binding pocket.{15221} Recently, SB 202190 has been used to elucidate the roles of p38 MAP kinases in inflammatory cytokine expression, nicotine-induced receptor expression, and HIV-mediated depressive disorder.{21463,21466,21467}  

 

Available on backorder

SKU: 10010399 - 50 mg Category:

Description

A selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively; at 10 μM, has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs)


Formal name: 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-phenol

Synonyms: 

Molecular weight: 331.3

CAS: 152121-30-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|p38 MAPK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling|p38 MAPK Signaling||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS||Research Area|Neuroscience|Behavioral Neuroscience|Addiction Research||Research Area|Neuroscience|Behavioral Neuroscience|Depression